Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial

O. van de Rest, J.M. Geleijnse, F.J. Kok, W.A. van Staveren, C. Dullemeijer, M.G.M. OldeRikkert, A.T.F. Beekman, C.P.G.M. de Groot

Research output: Contribution to journalArticleAcademicpeer-review

236 Citations (Scopus)

Abstract

Background: High intake of n-3 polyunsaturated fatty acids may protect against age-related cognitive decline. However, results from epidemiologic studies are inconclusive, and results from randomized trials in elderly subjects without dementia are lacking. Objective: To investigate the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on cognitive performance. Methods: Double-blind, placebo-controlled trial involving 302 cognitively healthy (Mini-Mental State Examination score > 21) individuals aged 65 years or older. Participants were randomly assigned to 1,800 mg/d EPA¿DHA, 400 mg/d EPA¿DHA, or placebo capsules for 26 weeks. Cognitive performance was assessed using an extensive neuropsychological test battery that included the cognitive domains of attention, sensorimotor speed, memory, and executive function. Results: The mean age of the participants was 70 years, and 55% were male. Plasma concentrations of EPA¿DHA increased by 238% in the high-dose and 51% in the low-dose fish oil group compared with placebo, reflecting excellent compliance. Baseline scores on the cognitive tests were comparable in the three groups. Overall, there were no significant differential changes in any of the cognitive domains for either low-dose or high-dose fish oil supplementation compared with placebo. Conclusions: In this randomized, double-blind, placebo-controlled trial, we observed no overall effect of 26 weeks of eicosapentaenoic acid and docosahexaenoic acid supplementation on cognitive performance
LanguageEnglish
Pages430-438
JournalNeurology
Volume71
Issue number6
DOIs
Publication statusPublished - 2008

Fingerprint

Eicosapentaenoic Acid
Docosahexaenoic Acids
Fish Oils
Randomized Controlled Trials
Placebos
Neuropsychological Tests
Executive Function
Omega-3 Fatty Acids
Double-Blind Method
Compliance
Capsules
Dementia
Epidemiologic Studies

Keywords

  • fatty-acid-composition
  • serum cholesteryl esters
  • verbal-learning test
  • erythrocyte-membranes
  • docosahexaenoic acid
  • alzheimer-disease
  • normative data
  • dementia
  • risk
  • plasma

Cite this

@article{bdf2c675cd6d4cc0b424a7bd4ea02b62,
title = "Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial",
abstract = "Background: High intake of n-3 polyunsaturated fatty acids may protect against age-related cognitive decline. However, results from epidemiologic studies are inconclusive, and results from randomized trials in elderly subjects without dementia are lacking. Objective: To investigate the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on cognitive performance. Methods: Double-blind, placebo-controlled trial involving 302 cognitively healthy (Mini-Mental State Examination score > 21) individuals aged 65 years or older. Participants were randomly assigned to 1,800 mg/d EPA¿DHA, 400 mg/d EPA¿DHA, or placebo capsules for 26 weeks. Cognitive performance was assessed using an extensive neuropsychological test battery that included the cognitive domains of attention, sensorimotor speed, memory, and executive function. Results: The mean age of the participants was 70 years, and 55{\%} were male. Plasma concentrations of EPA¿DHA increased by 238{\%} in the high-dose and 51{\%} in the low-dose fish oil group compared with placebo, reflecting excellent compliance. Baseline scores on the cognitive tests were comparable in the three groups. Overall, there were no significant differential changes in any of the cognitive domains for either low-dose or high-dose fish oil supplementation compared with placebo. Conclusions: In this randomized, double-blind, placebo-controlled trial, we observed no overall effect of 26 weeks of eicosapentaenoic acid and docosahexaenoic acid supplementation on cognitive performance",
keywords = "fatty-acid-composition, serum cholesteryl esters, verbal-learning test, erythrocyte-membranes, docosahexaenoic acid, alzheimer-disease, normative data, dementia, risk, plasma",
author = "{van de Rest}, O. and J.M. Geleijnse and F.J. Kok and {van Staveren}, W.A. and C. Dullemeijer and M.G.M. OldeRikkert and A.T.F. Beekman and {de Groot}, C.P.G.M.",
year = "2008",
doi = "10.1212/01.wnl.0000324268.45138.86",
language = "English",
volume = "71",
pages = "430--438",
journal = "Neurology",
issn = "0028-3878",
publisher = "American Academy of Neurology",
number = "6",

}

Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. / van de Rest, O.; Geleijnse, J.M.; Kok, F.J.; van Staveren, W.A.; Dullemeijer, C.; OldeRikkert, M.G.M.; Beekman, A.T.F.; de Groot, C.P.G.M.

In: Neurology, Vol. 71, No. 6, 2008, p. 430-438.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial

AU - van de Rest, O.

AU - Geleijnse, J.M.

AU - Kok, F.J.

AU - van Staveren, W.A.

AU - Dullemeijer, C.

AU - OldeRikkert, M.G.M.

AU - Beekman, A.T.F.

AU - de Groot, C.P.G.M.

PY - 2008

Y1 - 2008

N2 - Background: High intake of n-3 polyunsaturated fatty acids may protect against age-related cognitive decline. However, results from epidemiologic studies are inconclusive, and results from randomized trials in elderly subjects without dementia are lacking. Objective: To investigate the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on cognitive performance. Methods: Double-blind, placebo-controlled trial involving 302 cognitively healthy (Mini-Mental State Examination score > 21) individuals aged 65 years or older. Participants were randomly assigned to 1,800 mg/d EPA¿DHA, 400 mg/d EPA¿DHA, or placebo capsules for 26 weeks. Cognitive performance was assessed using an extensive neuropsychological test battery that included the cognitive domains of attention, sensorimotor speed, memory, and executive function. Results: The mean age of the participants was 70 years, and 55% were male. Plasma concentrations of EPA¿DHA increased by 238% in the high-dose and 51% in the low-dose fish oil group compared with placebo, reflecting excellent compliance. Baseline scores on the cognitive tests were comparable in the three groups. Overall, there were no significant differential changes in any of the cognitive domains for either low-dose or high-dose fish oil supplementation compared with placebo. Conclusions: In this randomized, double-blind, placebo-controlled trial, we observed no overall effect of 26 weeks of eicosapentaenoic acid and docosahexaenoic acid supplementation on cognitive performance

AB - Background: High intake of n-3 polyunsaturated fatty acids may protect against age-related cognitive decline. However, results from epidemiologic studies are inconclusive, and results from randomized trials in elderly subjects without dementia are lacking. Objective: To investigate the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on cognitive performance. Methods: Double-blind, placebo-controlled trial involving 302 cognitively healthy (Mini-Mental State Examination score > 21) individuals aged 65 years or older. Participants were randomly assigned to 1,800 mg/d EPA¿DHA, 400 mg/d EPA¿DHA, or placebo capsules for 26 weeks. Cognitive performance was assessed using an extensive neuropsychological test battery that included the cognitive domains of attention, sensorimotor speed, memory, and executive function. Results: The mean age of the participants was 70 years, and 55% were male. Plasma concentrations of EPA¿DHA increased by 238% in the high-dose and 51% in the low-dose fish oil group compared with placebo, reflecting excellent compliance. Baseline scores on the cognitive tests were comparable in the three groups. Overall, there were no significant differential changes in any of the cognitive domains for either low-dose or high-dose fish oil supplementation compared with placebo. Conclusions: In this randomized, double-blind, placebo-controlled trial, we observed no overall effect of 26 weeks of eicosapentaenoic acid and docosahexaenoic acid supplementation on cognitive performance

KW - fatty-acid-composition

KW - serum cholesteryl esters

KW - verbal-learning test

KW - erythrocyte-membranes

KW - docosahexaenoic acid

KW - alzheimer-disease

KW - normative data

KW - dementia

KW - risk

KW - plasma

U2 - 10.1212/01.wnl.0000324268.45138.86

DO - 10.1212/01.wnl.0000324268.45138.86

M3 - Article

VL - 71

SP - 430

EP - 438

JO - Neurology

T2 - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -